Navigation Links
Pharsight Files Application for Nasdaq Capital Market Listing
Date:9/18/2007

MOUNTAIN VIEW, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has filed an application to list its common stock on the Nasdaq Capital Market. The Company will work with Nasdaq to complete the application process.

"This application is an important milestone for Pharsight," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Three years ago we embarked upon a strategy that we believed would lead to profitable revenue growth and enhanced value for our stockholders. Since that time, we have delivered consistent, positive net income and revenue growth. We believe the successful listing of Pharsight's common stock on the Nasdaq Capital Market will encourage an increase in our valuation, one that is more in-line with companies with similar dynamics and one that more adequately reflects our long-term opportunities for growth."

As part of the Nasdaq application and approval process, the Company must meet certain eligibility criteria. The Company believes it currently meets every eligibility criterion with the exception of a minimum bid price of $4. The Company's stockholders recently approved a reverse stock split, which, once completed, the Company believes will allow it to meet this final requirement.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com. Safe Harbor

This press release includes forward-looking statements, including statements regarding listing on the Nasdaq Capital Market, Pharsight's valuation and growth opportunities, the completion of a reverse stock split and Pharsight's stock price. These forward-looking statements involve risks and uncertainties, and factors that could cause actual results to differ materially include the following: changes in the demand for Pharsight's products and services; changes in Pharsight's operating strategies, pricing models or research and development focus; the failure to develop new products and services or to keep pace with technological changes; the failure of the market for Pharsight's products and services to develop as expected; the failure to generate additional sales from existing customers or to generate sales to new customers; the failure to meet customers' expectations; uncertainties involved in pharmaceutical drug development; changes in government regulation of the pharmaceutical industry; and uncertainties regarding the listing of our common stock on the Nasdaq Capital Market; and general market conditions. There can be no assurance that Pharsight's common stock will be approved for listing on the Nasdaq Capital Market. Further information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10-K, as filed with the Securities and Exchange Commission on June 27, 2007. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.

Contacts:

Investors Media

EVC Group EVC Group

Jennifer Beugelmans, 646-201-5447 Jennifer Saunders

Douglas Sherk, 415-896-6820 646-201-5431


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Novartis files application with FDA for Zometa
2. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
3. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
4. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
5. Personality profiles of gamblers and substance abusers are similar
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Venus Remedies Files 5th International Patent Application
8. Shoaib Akhtar files appeal against ban
9. AIIMS Official Files Complaint Against Venugopal
10. Glaxo Files Cancer Drug For Approval With FDA
11. Nigeria Files New Lawsuit Against Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... ... 2017 , ... Healthy living brand Moody Zook recently came ... With more and more people opting to go organic in their lifestyle, the ... to specific needs. , Moody Zook focused particularly on their newly launched activated ...
(Date:1/13/2017)... California (PRWEB) , ... January 13, 2017 , ... ... carbohydrates that raise blood sugar levels. Counting carbohydrates is as easy as checking ... the only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... taken on the challenge of providing additional organic alternatives for customers who have ... of the brand’s new line of all-natural activated charcoal products, Moody Zook Chief ...
(Date:1/13/2017)... PA (PRWEB) , ... January 13, 2017 , ... "We ... and attractive to wear," said one of two inventors from Virginia Beach, Va. , ... to normally mundane braces. , The accessories allow braces to be customized to ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology: